The purpose of this study is to bctlcr dcfinc scizurc actlvtty and to 111;lhc anticonvulsant therapy optimal. During a period of 4.5 ycxs, 57 1nf.lnls WIIII clinical evidcnl seizures underwent conlinuous EEG moniloring (C.I:.hl.. Device I~~slruttlcnl, LIJ, I N I I~U I I ) . C.I:.M. tr;lctllg sliuwcd wlntrc ;~cltvtly 111 R I (34.4 7 6 ) . and none in 26 (45.6 96). 20 of the 31 subjects with C.P.M. docu~llcntcd actlvlty and 20 of those 26 without, had alrudy begun anti-convulut~t tllcrapy at the beginning of C.F.M. moniloring. The efficacy of the anli-convulsant drugs was evaluated in 31 infants having both clinical and C.F.M. documented seizure activity. 20 infants began C.F.M. monitoring after, and I I before beginning anticonvulsant therapy. PhenobarbiL~I, the drug of first chaise, was efficacious in 4 out of the 27 cases, but useless in 16 of lhc 27. The best responce was obteined with lidocaine. efficacious in 14 out of 20 patients treated. In conclusion. 45.6 % of the clinical seizures have no C.F.M. equivalent. In the large pan of the cases. commonly used anti-convulsant drugs did 1:ot eliminate the seizure acttvity found on C.F.M. The persistent electrical seizurcs are considered lo bc damaging. Continuous neurophysiological monitoring is a very usefull means for evaluating thc cfficacy of antieonvulslnt therapy. p e r i n n t a l 11-1 i n s u l t 1-24 hours a f t e r r c c~r c u l n t i o n on ,:lutanute r e l e a s e and dopaminc (Dl) b l n d~n g s i t e s in p i g l e t brain ( i -7 
